-
Substantive Updates Part Four: Key Regulatory and Pricing Developments Affecting How Life Sciences Companies Bring Products to Market 7-2016 - July 2016
by Kendra A. Martello, Deputy Vice President, Strategic Operations at Pharmaceutical Research and Manufacturers of America (PhRMA) (Washington, DC), Gail L. Daubert, Partner at Reed Smith LLP
-
Substantive Updates Part III 7-2016 - July 2016
by Lynn A. Neils, Partner at Baker Botts L.L.P. (New York, NY)
-
Substantive Updates Part Two: What Women Leaders in Life Sciences Law Must Know About Crucial Intellectual Property Protection and Enforcement Strategies 7-2016 - July 2016
by Jennifer L. Fox, Shareholder at Brinks Gilson Lione, Kathleen Gersh, Senior Counsel at Loeb & Loeb LLP (New York, NY), Delphine W. Knight Brown, Partner at Axinn, Veltrop & Harkrider LLP (New York, NY), Zoya Marriott, Principal at Cornerstone Research
-
Tales from the Top on Effective Leadership 7-2016 - July 2016
by Maureen McGirr, Vice President, Office of Ethics, Global Compliance at Merck & Co., Inc., Maria E. Pasquale, SVP and Deputy General Counsel at Celgene Corporation, Averi Price, Chief Compliance Officer at Radius Health, Inc., Lisa B. Pensabene, Partner and Head of Life Sciences Litigation Practice at O’Melveny & Myers LLP (New York, NY)
-
Substantive Updates Part One: What Women Leaders in Life Sciences Law Must Know about Products Liability, Mass Torts and “Bet-the-Company” Litigation 7-2016 - July 2016
by Candace Camarata, Assistant General Counsel at C.R. Bard, Inc. (Murray Hill, NJ), Melissa A. Geist, Partner and Co-Chair, Life Sciences Health Industry Group at Reed Smith LLP (Princeton, NJ), Colleen M. Hennessey, Partner at Peabody & Arnold LLP (Boston, MA), Brandee J. Kowalzyk, Partner at Nelson Mullins Riley & Scarborough LLP (Atlanta, GA)
